Canada Atherosclerosis Therapeutics Market Analysis

Canada Atherosclerosis Therapeutics Market Executive Summary

Canada Atherosclerosis therapeutics market was valued at $224 Mn in 2022 and is estimated to reach $349 Mn in 2030, exhibiting a CAGR of 5.7% during the forecast period.

Atherosclerosis is a type of vein narrowing or obstruction brought on by plaque accumulation. White blood cells and bad cholesterol combine to form this plaque, which can interfere with the body's regular blood flow. It begins when the blood vessel' inner lining gets damaged, which makes it easier for harmful cholesterol to adhere to the walls. The body produces cells to clear it out, but occasionally they become lodged, which causes plaque to develop. This plaque has the potential to obstruct the passage, impairing blood flow and raising the danger of life-threatening issues including strokes and heart attacks. Atherosclerosis can be caused by a number of factors, including high blood pressure, high cholesterol, diabetes, obesity, smoking, having a family history of heart disease, lack of exercise, and eating an unhealthy diet.

About 1 in 12 Canadian adults over the age of 25, or 2.6 Mn people, were diagnosed with heart disease, with atherosclerosis being the most common underlying cause. The prevalence of atherosclerosis is closely linked to major risk factors for chronic diseases. Atherosclerosis is known to be aggravated by high blood pressure, bad cholesterol, and obesity. Of Canadians aged 12 and over, nearly half (48%) had at least one significant risk factor. Men are typically more at risk than women in lower age groups when it comes to atherosclerosis, which increases with age. It is important to address these risk factors for successful prevention and management of atherosclerosis, as women's risk increases after menopause to equal or even exceed men's.

AstraZeneca's Brilinta, a P2Y12 receptor antagonist used to prevent blood clots after a heart attack, is presently conducting a Phase 3 trial called BRIGHTER. The purpose of this experiment is to determine whether Brilinta can effectively lower severe adverse cardiovascular events in individuals who have elevated high-sensitivity C-reactive protein (hsCRP), a crucial indicator of inflammation, and stable coronary artery disease.

Novartis reached a major milestone in November 2023 when Health Canada approved Leqvio (inclisiran), a PCSK9 inhibitor. This approval is especially for the treatment of persons with mixed dyslipidemia or familial hypercholesterolemia who require additional lowering of LDL-C levels after statin therapy has been maximally tolerated. By receiving regulatory approval, Novartis has made a significant advancement in meeting the healthcare needs of people with these particular lipid problems by introducing a beneficial therapeutic alternative for high-risk patients.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Cardiovascular Diseases: About 1 in 12 persons in Canada have been diagnosed with heart disease, indicating a significant prevalence of cardiovascular disorders in the country. One prominent cause of this health issue is atherosclerosis, which increases the need for therapeutic medications that aim to mitigate its effects. The population of Canada is exposed to common risk factors, including obesity, high blood pressure, and unhealthy cholesterol levels. As a result, the need for effective atherosclerosis treatment measures in Canada is growing.

Aging Population: The increasing age of Canada's population contributes significantly to the older population's increased susceptibility to atherosclerosis, which in turn drives the expansion of the relevant drug market. According to Statistics Canada, the number of people 65 and older will nearly double to 26.4 million by 2037. The aging population's increased risk of developing Atherosclerosis underscores the growing importance of addressing the therapeutic needs associated with this cardiovascular condition.

Lifestyle-Related Risk Factors: The growing incidence of atherosclerosis is mostly due to the rising prevalence of lifestyle-related risk factors, such as sedentary behaviour and poor eating habits. This in turn drives the need for efficient medications to control and treat atherosclerosis and various medical issues related to it.

Market Restraints

Cost and Affordability: The exorbitant expense of atherosclerosis medications, especially new ones like PCSK9 inhibitors, makes them difficult for patients to get, especially those with limited insurance coverage or financial resources. In addition to costing people money, this fee puts pressure on public healthcare systems to efficiently use their limited resources.

Regulatory landscape: The rigorous regulatory clearance process in Canada may make it more difficult for new atherosclerosis medications to be available on time, which could limit patients' access to potentially life-changing medicines. The market's ability to grow may be impacted by this approval delay because it may make new treatments less accessible, which could limit the market's ability to grow overall and treat atherosclerosis to the greatest extent possible.

Patient Adherence: Long-term drug adherence is typically necessary for effective treatment of atherosclerosis, which can be difficult for certain individuals. Non-adherence can be caused by a variety of factors, including side effects, complex dosing schedules, and a lack of evident instant benefits. This can hinder the effectiveness of therapy and perhaps result in higher healthcare expenses due to complications.

Notable Recent Updates

• December 2021, Leqvio, the first and only small interfering RNA (siRNA) medication to lower low-density lipoprotein cholesterol with two doses a year following an initial dose and one at three months, was approved by the US Food and Drug Administration (FDA), according to Novartis.
• December 2021, Vesper Medical Inc. is a US-based medical technology firm that creates minimally invasive peripheral vascular devices. Royal Philips stated that it has inked a deal to purchase the company. With a sophisticated venous stent portfolio for the treatment of deep vein illness, Vesper Medical will further broaden Philips' line of diagnostic and therapeutic devices.

Healthcare Policies and Regulatory Landscape

The main regulatory agency in Canada is called Health Canada, and its job is to make sure that drugs and other healthcare items are safe, effective, and of high quality. Health Canada must approve new medications through a rigorous examination procedure before they can be marketed and sold in the nation, ensuring their efficacy and safety. Health Canada's specific division in charge of managing drug regulation is called the Pharmaceutical Drugs Directorate (previously known as the Therapeutic Products Directorate). The PDD is this department that thoroughly analyses drug applications, evaluating them for quality, safety, and efficacy prior to authorizing.

Competitive Landscape

Key Players

• Pfizer
• Novartis
• AstraZeneca
• Sanofi
• Bayer
• Johnson & Johnson
• Eli Lilly
• AbbVie
• Roche
• Teva Pharmaceutical Industries